Intelligent Bio Solutions (INBS) versus Its Peers Critical Contrast

Intelligent Bio Solutions (NASDAQ:INBS – Get Rating) is one of 223 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it contrast to its peers? We will compare Intelligent Bio Solutions to similar businesses based on the strength of its dividends, earnings, valuation, profitability, analyst recommendations, risk and institutional ownership.

Valuation & Earnings

This table compares Intelligent Bio Solutions and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Intelligent Bio Solutions	$440,000.00	-$8.31 million	-0.48
Intelligent Bio Solutions Competitors	$1.10 billion	$81.57 million	10.58

Intelligent Bio Solutions’ peers have higher revenue and earnings than Intelligent Bio Solutions. Intelligent Bio Solutions is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Intelligent Bio Solutions and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Intelligent Bio Solutions	-1,078.91%	-106.09%	-62.08%
Intelligent Bio Solutions Competitors	-1,355.92%	-145.04%	-26.44%

Analyst Ratings

This is a breakdown of current ratings and target prices for Intelligent Bio Solutions and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intelligent Bio Solutions	0	0	0	0	N/A
Intelligent Bio Solutions Competitors	888	3402	7588	172	2.58

As a group, “Surgical & medical instruments” companies have a potential upside of 21.50%. Given Intelligent Bio Solutions’ peers higher probable upside, analysts plainly believe Intelligent Bio Solutions has less favorable growth aspects than its peers.

Volatility & Risk

Intelligent Bio Solutions has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500. Comparatively, Intelligent Bio Solutions’ peers have a beta of 1.37, suggesting that their average share price is 37% more volatile than the S&P 500.

Institutional & Insider Ownership

2.3% of Intelligent Bio Solutions shares are owned by institutional investors. Comparatively, 45.8% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 1.9% of Intelligent Bio Solutions shares are owned by company insiders. Comparatively, 15.2% of shares of all “Surgical & medical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Intelligent Bio Solutions peers beat Intelligent Bio Solutions on 7 of the 10 factors compared.

Intelligent Bio Solutions Company Profile

(Get Rating)

Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.